© 2021 MJH Life Sciences and Formulary Watch. All rights reserved.
© 2021 MJH Life Sciences™ and Formulary Watch. All rights reserved.
December 01, 2020
FDA okayed the first drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen positive lesions in men with prostate cancer.
The drug is the first FDA-approved therapy for these rare genetic diseases.
November 03, 2020
Recalls of metformin products due to higher levels of the probable carcinogenic ingredient N-Nitrosodimethylamine (NDMA) than allowed continue.
October 06, 2020
The combination therapy of Opdivo plus Yervoy will treat the cancer caused by inhaling asbestos fibers.
September 22, 2020
Both recalls are due to sub-potency of drugs that treat hypothyroidism.
August 17, 2020
The drug’s indication for marginal zone lymphoma (MZL) may not be approved until February 2021.
July 13, 2020
Five other manufacturers have recalled the popular diabetes medication due to the presence of a the carcinogenic ingredient.
July 07, 2020
Gilead will present new data on virologic suppression in adults 65 years and older at AIDS 2020: Virtual this week.
June 23, 2020
Investigational treatment will target marginal zone lymphoma (MZL) and follicular lymphoma (FL).
June 16, 2020
The agency revoked its emergency use authorization (EUA) for the drug, while warning about a dangerous interaction with remdesivir.